RNAC (Cartesian Therapeutics) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RNAC Cartesian Therapeutics Inc RNAC
24 GF Score
Price $10.38
GF Value $0.29
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Cartesian Therapeutics Short-term investments?

Short-term investments only applies to insurance companies.

RNAC
24GF Score
Cartesian Therapeutics Inc RNAC
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cartesian Therapeutics (RNAC) Overvalued in 2026?

Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued. The current stock price of $10.38 is trading 3479.3% above its estimated GF Value™ of $0.29. GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.

Key valuation signals for RNAC:

  • Short-term investments:
  • GF Value™: $0.29 vs. price of $10.38 (3479.3% above fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cartesian Therapeutics Business Description

Other Exchanges 1S70:Germany
Address 7495 New Horizon Way, Frederick, MD, USA, 21703
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
24GF Score

Get the complete analysis for RNAC

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.38
Price
$0.29
GF Value